CHK2 Immunohistochemical Expression in Colon Cancer and its Relation with Clinicopathological Features and Outcome in Metastatic Colon Cancer PatientsKaren Bento Ribeiro1, Juliana da Silva Zanetti2, Alfredo Ribeiro Silva3, Fabiana Pansani2, Sergio Britto Garcia3, Omar Feres4, José Joaquim Ribeiro da Rocha4 and Fernanda Maris Peria1*
- *Corresponding Author:
- Fernanda Maris Peria
Departamento de Clínica, Médica da FMRP-USP
Divisão de Oncologia Clinica Av. Bandeirantes
3900, Ribeirão Preto-SP, Brazil
Tel/Fax: 55 16 3602-2304
E-mail: [email protected]
Received Date: September 20, 2014; Accepted Date: October 18, 2014; Published Date: October 20, 2014
Citation: Ribeiro KB, da Silva Zanetti J, Ribeiro Silva A, Pansani F, Garcia SB, et al. (2014) CHK2 Immunohistochemical Expression in Colon Cancer and its Relation with Clinicopathological Features and Outcome in Metastatic Colon Cancer Patients. J Cytol Histol 5:288. doi: 10.4172/2157-7099.1000288
Copyright: © 2014 Ribeiro KB, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: The DNA damage checkpoint pathway has been of interest to the field of cancer biology, since checkpoint defects result in the accumulation of altered genetic information, a central feature of carcinogenesis. Little is known about the role that CHK2 (checkpoint kinase 2) gene plays in colorectal cancer tumorigenesis. The purpose of this study was to evaluate CHK2 expression in metastatic colon cancer and correlate it with clinicopathological features and patient survival.
Methods: Tissues of primary tumors were obtained from 58 patients with metastatic colon cancer. The tissue microarray immunohistochemistry was the technique used to evaluate CHK2 expression. Statistical analysis used was SPSS17; p-value was set at <0.050. The relationship between the CHK2 immunohistochemical expression and the patients’ clinical and pathological features as well as survival data was reported.
Results: CHK2 expression was positive in 69% of the cases. CHK2 expression was associated with lymph node status (p=0.012) and survival (p=0.034). Negative CHK2 expression increased the chance of lymph node involvement (Odds ratio: 10.23, p=0.03). The global survival time of CHK2-negative patients was higher (72 versus 59 months); the same trend emerged for progression-free survival time (19 versus 13 months). The survival curves differed depending on CHK2 expression in patients with or without lymph node involvement; survival was lower in CHK2-positive. A larger number of deaths occurred in CHK2-positive. Multivariate regression analysis identified performance status ECOG (p=0.01), synchronous metastasis (p=0.037), tumor cell differentiation (p=0.029) and CHK2 expression (p=0.020) as independent factors for overall survival.
Conclusions: This study demonstrated that positive CHK2 expression in colon cancer indicates aggressiveness and impacts negatively patient survival and outcome. On the other hand, a negative expression indicates dissemination to lymph nodes.